Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shield Therapeutics ( (GB:STX) ).
Shield Therapeutics said China’s National Medical Products Administration has accepted a marketing authorisation application for its ferric maltol product ACCRUFeR, filed by local partner Beijing Aosaikang Pharmaceutical. The submission, backed by U.S. FDA data and a Phase 3 trial in Chinese adults with iron deficiency anemia and inflammatory bowel disease intolerant to standard oral iron, showed strong efficacy and tolerability.
The move positions Shield to tap into China’s rapidly expanding iron deficiency anemia market, forecast to grow from about $280 million in 2022 to more than $600 million by 2030. Acceptance of the filing marks a key step toward potential approval that would extend ACCRUFeR’s global reach and deepen Shield’s presence in Asia via its network of regional licensing partners.
The most recent analyst rating on (GB:STX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical momentum and positive corporate events, which are offset by significant financial challenges and valuation concerns. The strong technical indicators and strategic corporate developments provide optimism, but financial instability remains a critical risk.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics is a commercial-stage specialty pharmaceutical group focused on treating iron deficiency and iron deficiency anemia with its oral ferric maltol product, marketed as ACCRUFeR and FeRACCRU. The company sells ACCRUFeR in the U.S. through Viatris and has outlicensed rights across Europe, Canada, Asia-Pacific and Greater China, where partners commercialize or develop the drug in key growth markets.
Average Trading Volume: 2,291,991
Technical Sentiment Signal: Buy
Current Market Cap: £106.8M
For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.